Research Papers

25 of 2183 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
CXCL12 and CXCR4 as Potential Early Biomarkers for Luminal A and Luminal B Subtypes of Breast Cancer.
Motyka J; Gacuta E; Kicman A; Kulesza M; Malinowski P; Ławicki S.
Cancer Manag Res (Unknown)
Published: 2023
2/6 Transparent
Clinical Value of Combined Detection of Serum sTim-3 and CEA or CA19-9 for Postoperative Recurrence of Colorectal Cance…
Hong J; Chen X; Chen L; Wang Y; Huang B; Fang H.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Cell Cycle-Related lncRNAs as Innovative Targets to Advance Cancer Management.
Liang XR; Liu YF; Chen F; Zhou ZX; Zhang LJ; Lin ZJ.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Optimal Delivery of Follow-Up Care Following Treatment for Adults Treated for Ewing Sarcoma.
Digklia A; Dolcan A; Kucharczyk MA; Jones RL; Napolitano A.
Cancer Manag Res (Unknown)
Published: 2023
2/6 Transparent
Increased Platelet Distribution Width Predicts 3-Year Recurrence in Patients with Hepatocellular Carcinoma After Surgic…
Li H; Liu J; Yan S; Rao C; Wang L.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Socio-Demographic Factors and Other Predictors of Pap Test Uptake Among Women: A Retrospective Study in Ghana.
Mensah KB; Boamah Mensah AB; Yamoah P; Manfo J; Amo R; Wiafe E; Padayachee N; Bangalee V.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Metformin Induces a Caspase 3-Unrelated Apoptosis in Human Colorectal Cancer Cell Lines HCT116 and SW620.
Rosidi B; Priyatno D; Putra TP; Yusuf I.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Ly…
Lee YP; Yoon SE; Cho J; Ko YH; Oh D; Ahn YC; Kim WS; Kim SJ.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Taking Precautions When Targeting Ferroptosis in Cancer Patients [Letter].
Nikmah UA; Hidayat S; Situmorang JH.
Cancer Manag Res (Unknown)
Published: 2023
2/6 Transparent
Patient Perspectives and Side-Effects Experience on Chemotherapy of Non-Small Cell Lung Cancer: A Qualitative Study.
Zubair HM; Khan MA; Gulzar F; Alkholief M; Malik A; Akhtar S; Sharif A; Akhtar MF; Abbas M.
Cancer Manag Res (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
The Ratio of Monocyte to Apolipoprotein A1 is an Independent Predictor of Breast Cancer: A Retrospective Study.
Lin Z; Luo C; Yuan Y.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data.
Kim Y; Yamamoto S; Kato K.
Cancer Manag Res (Unknown)
Published: 2023
2/6 Transparent
Establishment and Validation of a Novel Prediction Model for Early Natural Biochemical Recurrence After Radical Prostat…
Lian B; Qu M; Zhang W; Dong Z; Chen H; Jia Z; Wang Y; Li J; Gao X.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: P…
Roof L; Geiger JL.
Cancer Manag Res (Unknown)
Published: 2023
2/6 Transparent
Implication of Ferroptosis in Cholangiocarcinoma: A Potential Future Target?
Yang M; Li M; Lyu Z; Yang Z.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer.
Liu X; Ma X; Ou K; Wang Q; Gao L; Yang L.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab.
Lopedote P; Shadman M.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The Role of Perioperative C-Reactive Protein in Predicting the Prognosis of Epithelial Ovarian Carcinoma.
Pan Q; Wei M; Lu M; Xu Y; Xie X; Li X.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Establishment and Characterization of Patient-Derived Xenograft Model of Non-Small-Cell Lung Cancer Derived from Malign…
Liao H; Zhou S; Chen S; Li J; Zhang Z; Meng L; Liu Q; Wu Y; He Y; Li M.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients Treated with Definitive Chemoradiotherapy for Locall…
Zhang G; Yang C; Zhao C; Xian F; Qing D; Guo Q; Song J; Liu X; Bie J.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cance…
Duan Y; Qin W; Yang L; Zou B; Qie W; Song R; Xue L; Wang L.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country.
Poh ME; How SH; Ho GF; Pang YK; Hasbullah HH; Tho LM; Muhamad Nor I; Lim BC; Ho KF; Thiagarajan M; Samsudin A; Omar A; Ong CK; Soon SY; Tan JYK; Zainal Abidin MA.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Improvements in Survival and Early Retirement Rates - Real-World Evidence on Danish Breast Cancer Patients 2004-2018.
Khan H; Rudolfsen JH; Olsen J; Borgquist S; Poulsen PB.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Enhanced Glycolysis Confers Resistance Against Photon but Not Carbon Ion Irradiation in Human Glioma Cell Lines.
Vashishta M; Kumar V; Guha C; Wu X; Dwarakanath BS.
Cancer Manag Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management.
Fawaz A; Abdel-Rahman O.
Cancer Manag Res (Unknown)
Published: 2022
2/6 Transparent